Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies

Poster featuring Phase 2 results to be presented at SNO includes additional data beyond topline results previously announced in July 2026

NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three posters on ongoing studies of safusidenib, its selective investigational inhibitor of mutant IDH1, will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12â15, 2026, in Philadelphia, PA. Positive topline Phase 2 J201 results were announced in July; additional key data will be featured in the SNO poster.

"Patients with IDH1-mutant glioma are often diagnosed in their 30s and 40s and may live with their disease for many years, underscoring the importance of targeted treatments that can deliver durable responses with a consistent safety profile," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We look forward to sharing updated Phase 2 results that speak to that need, as well as progress across our expanded safusidenib development program, with the clinicians and patient community working to advance care for people living with IDH1-mutant glioma."

Presentations Overview:

The materials will be made available in the Publications section of Nuvation Bio's website after the presentations. To meet representatives from Nuvation Bio, visit Booth #126.

About IDH1-mutant Glioma

Gliomas are the most common type of brain cancer in adults worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH-mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1, gliomas are not currently curable and prognosis worsens for those with high-risk features, including high grade tumors.

About Safusidenib

Safusidenib is an investigational, oral, brain-penetrant, selective inhibitor of mutant IDH1. It is being studied in patient populations with significant unmet medical need, including settings where there are limited or no approved targeted treatment options. In Phase 1 and Phase 2 clinical studies, safusidenib demonstrated encouraging clinical activity, including delayed disease progression and durable responses across a range of tumor grades and risk groups, with a favorable risk-benefit profile. These early findings support further investigation of safusidenib in the currently enrolling Phase 3 SIGMA study, as well as in the Phase 3 G307 study in regions where vorasidenib is not yet approved or accessible and the Phase 2 G209 study in patients whose cancer has progressed on vorasidenib.

In August 2026, the FDA granted Fast Track Designation to safusidenib for the treatment of IDH1-mutant glioma.

About the SIGMA (G203) Study

SIGMA is a pivotal Phase 3 study that will evaluate safusidenib compared to placebo as a maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. The pivotal portion of the study will enroll approximately 300 patients.

A separate, exploratory, non-pivotal cohort will evaluate safusidenib in participants with grade 3 IDH1-mutant oligodendroglioma who have not yet received chemotherapy or radiotherapy. The primary endpoint is objective response rate. This cohort is expected to enroll approximately 40 patients.

About Nuvation Bio

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).

Media and Investor Contacts

Nuvation Bio Investor Contact

JR DeVita

[email protected]

Nuvation Bio Media Contact

Kaitlyn Nealy

[email protected]

SOURCE Nuvation Bio Inc.

Share this article

Acquisition Marks Turpaz's First Entry into South Africa's Fragrance Market and Advances the Group's Strategy to Build an Integrated Regional Flavor and Fragrance Platform in Africa

CAESAREA, Israel, Nov. 2, 2026 /PRNewswire/ -- Turpaz Industries Ltd. (TASE: TRPZ), a global company that develops and manufactures flavors and fragrances, intermediates and specialty fine ingredients and markets and sells them in more than 100 countries around the world, announced the acquisition of 70% of the share capital of Sensory FX Proprietary Limited ("Sensory"), a privately held South African developer and manufacturer of flavors and fragrances, through its South African subsidiary Sunspray Solutions Proprietary Limited ("Sunspray"). The consideration for the 70% stake is approximately $10.6 million (approximately ZAR 177.4 million), paid upon signing, plus additional consideration based on Sensory's performance during the period from March 1, 2026 to February 28, 2027. The transaction closed upon signing and was financed through long-term bank debt.

Sensory's existing shareholders, who have extensive experience in the South African flavor and fragrance industry, will retain the remaining 30% of Sensory's shares and will continue to lead its management and operations in the coming years. The agreement includes mutual put/call options for the remaining shares, exercisable from two or three years after closing, depending on the shareholder, at a price based on Sensory's business performance through the exercise date, payable in cash or in Turpaz shares at the shareholders' election.

Karen Cohen Khazon, Chief Executive Officer of Turpaz Industries, said, "We are excited to welcome Sensory and its experienced, professional team to the Turpaz Group. This acquisition is an important step in implementing Turpaz's growth strategy by expanding our presence in emerging markets and leveraging synergies across the Group. For the first time, Turpaz is entering the fragrance market in South Africa, and the acquisition provides a foundation for further developing a regional platform for flavors and fragrances across Africa. By combining Sensory's local development and manufacturing capabilities with Turpaz's expertise, technologies, broad product portfolio and global presence, we will be able to expand the solutions we offer our customers and pursue further growth opportunities across the continent."

François Strydom, Chief Executive Officer and a shareholder of Sensory, said, "We've always believed that South Africa could produce a fragrance and flavour company capable of competing with the very best in the world. This partnership validates that belief and marks an exciting new chapter for SensoryFX. We are proud to join the Turpaz Group and look forward to what we can achieve together."

Joseph Muhohoma, Vice President of Research and Development and a shareholder of Sensory, added, "We believe that joining Turpaz will enable us to expand the range of solutions we offer our customers, deepen our presence in the markets in which we operate, enter new markets and capture additional growth opportunities across the continent."

Founded in 1999, Sensory develops, manufactures and markets flavors and fragrances and a range of solutions for the food and beverage, personal care, home fragrance and consumer products industries. Sensory is one of the few independent local manufacturers of fragrance extracts in South Africa, and serves a broad and diverse customer base in South Africa and in additional markets across Africa.

Sensory operates a leased production site and a state-of-the-art R&D center, opened approximately a year ago, in the Johannesburg area, staffed by perfumers and flavorists with many years of experience, and employs 75 people. Sensory's operations are located in close proximity to Turpaz's existing South African businesses â Sunspray, which specializes in spray-drying solutions for the food and beverage industry, and Nicola-J, which operates in the flavor sector.

In its fiscal year ended February 28, 2026, Sensory generated revenues of $10.9 million, up approximately 18% from $9.2 million in the prior fiscal year. Gross profit was $5.7 million, operating profit was $2.0 million, EBITDA was $2.4 million and net profit was $1.7 million, compared with gross profit of $4.7 million, operating profit of $1.5 million, EBITDA of $1.8 million and net profit of $1.1 million in the prior fiscal year. These figures are based on adjusted management accounts prepared in accordance with IFRS, excluding one-time, non-recurring expenses that will not continue following the completion of the transaction.

The acquisition of Sensory marks Turpaz's first entry into the South African fragrance market and represents a further strategic step in expanding the Group's geographic footprint and strengthening its presence in Africa. The acquisition will enable Turpaz to advance the establishment of an integrated regional flavor and fragrance platform in Africa, built on local development and manufacturing capabilities combined with the know-how, technologies and resources of the global Group.

The combination of the businesses is expected to generate commercial, technological and operational synergies through the integration of know-how, R&D capabilities, product portfolios and procurement, to broaden the range of solutions offered to customers, to deepen activity in existing markets and to create cross-selling opportunities and access to new customers and markets. In addition, combining Sensory's local fragrance manufacturing capabilities with Turpaz's global expertise, technologies and product portfolio is expected to enable a fast, flexible and tailored response to customer needs in South Africa and in other markets across the continent.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, Turpaz's expectations with respect to the establishment of an integrated regional flavor and fragrance platform in Africa, the realization of commercial, technological and operational synergies from the acquisition of Sensory, expected cross-selling opportunities and expansion into new customers and markets, and the put/call options for the remaining shares of Sensory. Such forward-looking statements are based on estimates, projections and assumptions of Turpaz's management as of the date of this release, which may not materialize, in whole or in part, or may materialize in a manner different from that anticipated, including as a result of changes in market conditions, changes in the business environment and the materialization of risk factors detailed in section 1.28 of Chapter A of the Company's Annual Report for 2025.

About Turpaz Industries Ltd.

Turpaz Industries Group is a global company operating in the fields of flavor, fragrance and specialty fine ingredients. The Group develops, manufactures, markets and sells thousands of products to more than 5,100 customers in over 100 countries around the world. Turpaz operates 31 manufacturing sites, research and development centers, laboratories and sales, marketing and regulatory offices worldwide, and employs more than 1,200 people. Since 2017, the Company has completed 29 acquisitions worldwide, which have expanded its geographic footprint, strengthened its development and manufacturing capabilities and broadened the range of products and solutions offered to its customers. The Company's business strategy is based on organic growth at a rate higher than market growth, and the successful and systematic implementation of strategic acquisitions.

For more information, please visit Turpaz's website, at: https://www.turpaz.co.il/Investors.

International Investor Relations

Ehud Helft

EK Global Investor Relations

[email protected]  

SOURCE Turpaz Industries

Share this article

TOYO to Exhibit at RE+ 2026 and Participate in ROTH Solar & Storage Symposium

TOKYO, Nov. 2, 2026 /PRNewswire/ -- TOYO Co., Ltd (Nasdaq: TOYO; OTC: TOYWF) ("TOYO" or the "Company"), a solar manufacturing company, today announced that it will exhibit at RE+ 2026, taking place November 16â19, 2026, at the Las Vegas Convention Center in Las Vegas, Nevada. The Company will also participate in the 13th Annual ROTH Solar & Storage Symposium, held during RE+ on November 17, 2026.

TOYO will exhibit at Booth #N3136 from November 17 to 19. Visitors can meet the TOYO team to learn about the Company's high-efficiency solar products and its U.S. manufacturing operations in Humble, Texas.

TOYO management will participate in one-on-one meetings with institutional investors during the ROTH symposium. Attendance at the symposium is by invitation only for ROTH clients. Interested investors should contact their ROTH sales representative to schedule a meeting. Other investors and members of the media who wish to meet with TOYO management during RE+ may contact TOYO Investor Relations at [email protected].

About TOYO Co., Ltd.

TOYO is a solar manufacturing company that is committed to becoming a vertically integrated solar manufacturer in the global market, integrating the upstream production of wafers and silicon, midstream production of solar cells, downstream production of photovoltaic modules, and potentially other stages of the solar power supply chain. TOYO is well-positioned to produce high-quality solar cells and modules at a competitive scale and cost.

Contact Information

For TOYO Co., Ltd.

[email protected] 

Crocker Coulson

Email: [email protected]

Tel: (646) 652-7185

SOURCE TOYO Co., Ltd

Share this article

Royal Purple Unveils New Three-Tier Performance Motor Oil Lineup at AAPEX 2026

High Performance, new Ultimate High Performance, and Extreme Performance Racing give drivers a clear path from daily driving to the track, with the lineup arriving at retail beginning January 2027.

LAS VEGAS, Nov. 2, 2026 /PRNewswire/ -- Royal Purple®, the synthetic lubricant brand recognized by its signature purple oil, tomorrow announces a reimagined passenger car motor oil lineup, which it will unveil when AAPEX 2026 opens Tuesday morning. The new three-tier Performance Line â High Performance, Ultimate High Performance, and Extreme Performance Racing â consolidates a range of legacy products with three clearly defined choices, each matched to specific vehicle demands.

"The new lineup brings our passenger car motor oils together into three focused tiers, making it easier than ever for customers to find the right fit," said Royal Purple Jonathan Vilardo, Product Management Director. "Beyond streamlining the selection process, the new line delivers a true upgrade in performance, bringing our highest level of synthetic engineering directly to everyday drivers."

Three Tiers, One Clear Choice

High Performance â The everyday upgrade for daily drivers, commuters, and family vehicles. Designed to prevent deposits and sludge, preserve engine performance, and protect against wear, High Performance carries forward the trusted formulation customers rely on today with a new name and look.

Ultimate High Performanceâ Engineered for global compatibility across new and high-mileage gasoline and light-duty diesel vehicles, Ultimate High Performance is the upgrade for drivers who want more from every mile. Formulated with the brand's proprietary Synerlec® additive technology, a revolutionary advancement designed to meet the needs of modern engines and emissions systems, Ultimate High Performance removes engine sludge and deposits, reduces engine wear, and provides long-term engine protection.

Extreme Performance Racing â Built for the track. Extreme Performance Racing pairs the reformulated proprietary Synerlec® additive technology with elevated levels of ZDDP to protect engines in the most punishing conditions. It is the top-tier choice for competition and high-stress engine builds.

See the Line at AAPEX 2026

Attendees can see all three tiers in person at the Royal Purple booth, V3861, at the Venetian Expo and AAPEX Forum, Nov. 3-5, 2026. The Royal Purple team will walk retailers, distributors, installers, and media through the new lineup, packaging, and January retail rollout.

"AAPEX is where the aftermarket comes together, so it's the right place to introduce the next chapter of Royal Purple® motor oil portfolio," said Lesley Reed, Senior Sales Director Consumer Sales "Drivers today want better performance, but they also want to feel confident they're choosing the right oil. Three clear tiers take the guesswork out of it and make it easier than ever to Choose Purple."

Media interviews and product briefings are available at the show by appointment. To schedule, contact Ed Walsh, RP Agency | 318.465.0138 | [email protected].

Availability

The Royal Purple Performance Line will be available at retail and through distribution partners beginning January 2027.

For more information, visit www.royalpurple.com/aapex2026/

Media kit: Royal Purple Media Kit

About Royal Purple®

Royal Purple® is a leader in high-performance synthetic lubricants trusted by customers who want the best for their vehicles. From professional technicians to automotive enthusiasts and racers, Royal Purple is relied on for advanced lubrication and engine protection. Manufactured by Calumet Branded Products, LLC in Porter, Texas, Royal Purple has delivered premium synthetic oil solutions since 1986. Its proprietary Synerlec® additive technology enhances oil film strength, delivering superior protection, improved efficiency, and extended drain intervals. From racing and powersports to commercial trucking, fleets, and passenger vehicles, Royal Purple products are designed to optimize performance and protect critical engine components. Royal Purple continues to set the standard in lubrication performance and innovation. Calumet Branded Products is a wholly owned subsidiary of Calumet, Inc. (NASDAQ: CLMT). To learn more, visit royalpurple.com.

SOURCE Calumet, Inc.

Share this article

Study to assess desalination's potential to make up to 500,000 acre-feet of water available for the region

PHOENIX, Nov. 2, 2026 /PRNewswire/ -- Arcadis (EURONEXT: ARCAD), the world's leading company delivering sustainable design, engineering, and consultancy solutions for natural and built assets, today announced that it will serve as the lead engineering firm supporting the study of the proposed Northern Gulf of California Desalination Project concept. Working alongside Sacyr Water and the wider project team, Arcadis will provide engineering and technical analysis to support the Water Infrastructure Finance Authority of Arizona (WIFA) during the multi-stage appraisal process. WIFA's Board of Directors has approved Stage 1.

Arizona continues to evaluate opportunities to diversify long-term water supply for the region. WIFA's appraisal process is designed to evaluate potential new water sources and determine their technical, financial, environmental, cultural, and regulatory viability. Stage 1 authorizes the initial analysis and does not represent a decision regarding project development or future funding, which WIFA will evaluate separately based on the results of the appraisal.

The appraisal study will explore the viability of a desalination facility and associated conveyance infrastructure that would ultimately make up to 500,000 acre-feet of water supply. A distinctive element of the proposed concept is the evaluation of geothermal energy as a potential renewable energy source for the desalination and conveyance system. The study is structured across six tasks: project management; technical evaluations; environmental and cultural evaluations; regulatory and contractual evaluations; society and community evaluations; and cost, financial and commercial evaluations. Arcadis leads the technical, environmental, and regulatory evaluation work and contributes to the other elements of the appraisal alongside the broader project team.

Heather Polinsky, CEO, Arcadis said: "Reliable, resilient water supplies are essential for Arizona's communities, now and for generations to come. This appraisal will give WIFA the technical information it needs to assess whether desalination, supported by renewable energy, could strengthen the region's long-term water security. With the potential to make up to 500,000 acre-feet of water available, the concept deserves careful examination. Working alongside Sacyr Water, we bring together Arcadis' expertise in water, desalination, infrastructure and renewable energy to help WIFA understand what is possible and make informed decisions about the region's future water supply."

ABOUT ARCADIS

Arcadis is the world's leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets. We are around 34,000 architects, data analysts, designers, engineers, project planners, waterâ¯managementâ¯and sustainability experts, all driven by our passion for improving quality of life. As part of our commitment to accelerating a planet positive future, we work with our clients to make sustainable project choices, combining digital and human innovation, and embracing future-focused skills across the environment, energy and water, buildings, transport, and infrastructure sectors. Weâ¯operateâ¯in over 30â¯countries, andâ¯reported â¬4.9â¯billion in gross revenues for 2025.â¯

Learn more atâ¯www.arcadis.comâ¯

SOURCE Arcadis

Share this article

Industry Takedown of Botnet Hidden in More Than 1.3 Million TV Set-Top Boxes across 200 Countries

Google, Plume, TrendAIâ¢, Lumen, HUMAN Security, Synthient and Japan's National Police Agency form coordinated effort combining security research, threat intelligence and network expertise to identify and disrupt X.CPE botnet

MOUNTAIN VIEW, Calif., Nov. 2, 2026 /PRNewswire/ -- Today, a group of private and public sector partners announced a coordinated takedown of X.CPE, a global botnet hidden in more than 1.3 million set-top boxes across more than 200 countries. Hidden on devices before they were ever sold, the botnet used subscribers' devices and home internet connections without their knowledge or consent. This takedown was led by Google, Plume, TrendAIâ¢, Lumen, HUMAN Security and Synthient, along with Japan's National Police Agency.

"Operations like this raise the cost for criminals and show that the infrastructure they rely on isn't out of reach," said Charley Snyder, Head of Disruption Operations at Google Threat Intelligence Group. "Disrupting X.CPE took partners across industry working together. It's proof that collaboration is one of the most powerful tools we have against threats that cross borders and industries."

A familiar device hiding an unfamiliar threat

X.CPE was embedded in firmware, the software that controls a device's basic operations, before set-top boxes reached subscribers' homes. X.CPE was built to evade pre-release security checks, and Google has since updated its review process in response, as well as banned the responsible OEM and any future subsidiaries or affiliates from making devices with preloaded Google apps. Unlike infections that depend on a user opening a suspicious attachment or installing an application, this threat arrived as part of the device itself. Subscribers received no consent request, notification or opt-out options.

Google, Plume, TrendAIâ¢, Lumen, HUMAN Security, Synthient, working with Japan's National Police Agency, carried out a coordinated disruption campaign against X.CPE. Each organization contributed in its own way, applying its expertise in connected-device security, malware analysis, network visibility and digital fraud to analyze the botnet and disrupt its operations.

Together they dismantled a threat hiding behind seemingly routine device activity: software embedded in TV set-top boxes that gave botnet controllers remote access and allowed them to exploit home broadband connections without subscriber consent. The takedown also disrupted the command-and-control domains that operate the criminal affiliates' malware modules. Because these affiliates distribute their modules through channels beyond X.CPE, Google assesses that taking down these domains will sever access to at least 10 million additional compromised devices.

The effort demonstrates the importance of connecting intelligence across organizations to confront threats that cross technology and network boundaries. By bringing together distinct perspectives on compromised devices, malicious software and internet traffic, the partners supported a coordinated takedown aimed at disrupting unauthorized access and monetization and addressing risks to subscriber privacy, broadband resources and trust in connected devices.

Turning home broadband into a business without permission

The botnet generated revenue from compromised devices in a variety of ways, including: reselling bandwidth, delivering video content, ad fraud, loading additional backdoors and, in earlier versions, installing apps for payment.

Residential proxy software allowed third-party traffic to pass through subscribers' internet connections, using their home internet addresses and bandwidth without permission. Researchers also found collection of device, network and account information, alongside persistent remote access capabilities.

For service providers, the findings highlight a supply chain risk that may not be apparent from a device's everyday performance. A functioning streaming box can still generate unexplained traffic and undermine trust in the broadband service.

"Protecting the connected home requires visibility into threats that subscribers cannot see and should not be expected to detect," said Chris Griffiths, Chief Technology Officer at Plume. "By contributing broadband intelligence to this joint effort, we helped expose hidden supply chain risks and support coordinated action to make networks safer for service providers and their subscribers."

Complementary expertise, coordinated action

The partners contributed to the Google-led effort to disrupt X.CPE:

TrendAIâ¢

Robert McArdle, Director of Cybercrime Research at TrendAIâ¢

"We applaud Google's decisive action in removing this threat. Our research identified over 1.3 million devices affected by this campaign. That's millions of households and businesses completely unaware that their equipment was being used as an accessory in active criminality - whether defrauding advertisers or piggybacking on their connections to carry out other attacks via residential proxies - which would commonly include identity theft impersonating people in their region. This action by Google and research partners significantly sets back these attackers, and TrendAI research will be watching them closely if they attempt to rebuild."

HUMAN

Gavin Reid, CISO at HUMAN

"Compromised-device networks are sustained by profit: operators take control of devices and household connections without consent, then monetise that access through proxy services and various fraud activities. Group action, as exemplified in this operation, interrupts the infrastructure needed for monetisation, raising the cost of operating these networks and weakening the incentives that sustain them. "

SYNTHIENT

Benjamin Brundage, CEO at Synthient.

"Illicit pay-per-install networks provide a significant backbone to the larger fraud ecosystem, powering everything from direct ad fraud to unregulated proxy networks that push credential stuffing and DDoS botnets. The takedown of X.Cpe helps protect this space as a whole, as well as the unsuspecting consumers victimized by this scheme." - Benjamin Brundage

Research and resources:

Google: https://cloud.google.com/blog/topics/threat-intelligence/shutting-the-door-on-the-xcpe-botnet

Plume: http://www.plume.com/xcpe-botnet-whitepaper-pdf

TrendAIâ¢: https://www.trendaisecurity.com/en-us/resources-insights/trendai-security-blog/trendaitm-research-helps-disrupt-android-tv-botnet-of-more-than-13-million-pre-infected-devices 

About Plume

Plume provides an AI-powered platform that enables internet service providers improve connectivity, security and the subscriber experience. Combining cloud-managed Wi-Fi, network intelligence and customer care orchestration, Plume helps service providers across more than 60 countries build subscriber confidence and operate more efficiently. More details about Plume.

About TrendAIâ¢

TrendAIâ¢, the global AI security leader and enterprise business unit of Trend Micro, empowers organizations with full AI visibility, governance, and consolidated security that inspires confidence, drive innovation, and eliminate risk. Trusted by the largest enterprises and governments across 185 countries, TrendAI⢠secures the entire organization, from identities to infrastructure to data. Global Fortune 500 companies rely on TrendAI⢠to stop threats up to 115 days earlier, powered by world-leading threat and attack intelligence. More details about trendaisecurity.com.

About Lumen

Lumen Technologies connects people, data and applications through its network and technology services. Its Black Lotus Labs threat research and operations team uses global network visibility to identify malicious activity, generate threat intelligence and help protect businesses and the internet. More details about Lumen Technologies.

About HUMAN Security

HUMAN Security helps organizations protect digital experiences by detecting and disrupting automated threats, fraud and abuse. Its technology and threat intelligence help enterprises and platforms verify digital interactions and establish trust across the customer journey. More details about humansecurity.com.

About Synthient

Synthient provides intelligence to identify residential proxies, VPNs and bot infrastructure, helping organizations assess traffic risk and investigate abuse. Its researchers analyze proxy networks, botnets and adversary infrastructure to expose emerging threats. More details about Synthient.

SOURCE Plume Design, Inc.

Share this article

Five Physicians in St. Louis, Milwaukee, and Chicago will provide greater access to high-quality fertility care closer to home

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Ivy Fertility, a leading national fertility company focused on compassionate and comprehensive familyâbuilding care, today announced the launch of Sage Reproductive Center, a new Midwestern fertility practice bringing together four reproductive endocrinologists and an experienced obstetrician-gynecologist to serve patients across six clinics in St. Louis, Milwaukee and Chicago.

The launch marks Ivy Fertility's expansion into three new states in the Midwest and reflects the company's continued commitment to expanding access to high-quality, personalized fertility and reproductive care. Sage Reproductive Center will offer comprehensive services spanning fertility evaluation and treatment, fertility preservation, IVF, male infertility, LGBTQIA+ and third-party reproduction, recurrent pregnancy loss and other reproductive health needs.

The founding physician partners of Sage Reproductive Center include reproductive endocrinologists Amber R. Cooper, MD, MS; Ellen Hayes, MD; Fabiola Balmir, MD; and Juan Alvarez, MD, alongside Sara Rizk, MD, a board-certified obstetrician and gynecologist and experienced gynecologic surgeon.

Together, the physicians bring extensive clinical experience and a shared commitment to evidence-based medicine, exceptional patient care and supporting patients across the many paths to fertility preservation and family building.

Supported by Ivy Fertility's physician-led model and established administrative, operational and technological infrastructure, Sage Reproductive Center enables its physicians to remain focused on delivering individualized care while providing patients with the resources and support of a national fertility organization.

"What makes Sage Reproductive Center special is the physicians who are coming together to build it," said Amber Cooper, MD, MS. "We share a commitment to excellent medicine, thoughtful patient care and giving patients the information and options they need to make decisions about their reproductive health and family building. I'm excited about what we can create together for patients across the Midwest."

"Sage Reproductive Center gives us the opportunity to build a practice around the kind of care I believe in: excellent medicine, individualized treatment and genuine compassion," said Ellen Hayes, MD. "I'm excited to continue caring for patients in Milwaukee and to help people navigate their own unique paths to fertility preservation and family building."

"There is something special about bringing together physicians who share the same commitment to excellent medicine and compassionate care," said Fabiola Balmir, MD. "I'm excited to be part of Sage Reproductive Center and to bring this team's shared vision to patients throughout the Midwest."

Founding Physician Partners

Amber R. Cooper, MD, MS, is a board-certified reproductive endocrinologist and infertility specialist with extensive clinical and leadership experience in reproductive medicine. Dr. Cooper completed her OB-GYN residency and REI fellowship at Washington University in St. Louis and earned a Master of Science in Clinical Investigation. She is an internationally recognized expert in the use of artificial intelligence and automation in fertility care, and her clinical interests include IVF outcomes, fertility preservation, ovarian aging, genetics and hysteroscopic surgery.

Ellen Hayes, MD, is a board-certified reproductive endocrinologist and infertility specialist and OB-GYN who has cared for patients in Wisconsin for more than 15 years. A graduate of Loyola University Chicago, she completed her OB-GYN residency at the Medical College of Wisconsin and REI fellowship at Emory University. Dr. Hayes has been consistently recognized as a Top Doctor by both Milwaukee Magazine and MKE Lifestyle Magazine and is known for her evidence-based, collaborative approach and commitment to helping patients navigate their individual paths to family building.

Fabiola Balmir, MD, is a board-certified reproductive endocrinologist and infertility specialist with extensive experience in fertility and reproductive medicine. Originally from New York, Dr. Balmir graduated from Columbia University and earned her medical degree from Morehouse School of Medicine. She completed her OB-GYN residency at Stony Brook University Hospital, followed by fellowship training in Reproductive Endocrinology and Infertility at Magee-Womens Hospital. She has also served as Director of Medical Education and Outreach within an academic practice and has been recognized by U.S. News & World Report as a Patients Top Choice. Dr. Balmir is passionate about empowering patients with knowledge of their reproductive options and building meaningful connections throughout their care. She is fluent in French.

Juan Alvarez, MD, is a board-certified reproductive endocrinologist and infertility specialist. He earned his medical degree from the University of Illinois College of Medicine in Chicago and completed his OB-GYN residency at Emory University School of Medicine before completing his fellowship in Reproductive Endocrinology and Infertility at UCLA/Cedars-Sinai. Dr. Alvarez has particular expertise in third-party reproduction, fertility preservation, diminished ovarian reserve and the impact of obesity on fertility. As both a member of the LGBTQIA+ community and a fertility specialist, he has a special interest in LGBTQIA+ fertility care and education. He is passionate about patient education and building strong, collaborative relationships with his patients.

Sara Rizk, MD, is a board-certified obstetrician and gynecologist with fellowship training in pelvic surgery from Emory University. An experienced gynecologic surgeon and seasoned OB-GYN, Dr. Rizk has worked closely with reproductive endocrinologists and fertility patients throughout her career. She brings extensive surgical expertise and a collaborative, patient-centered approach to reproductive and women's health.

With the addition of the Sage Reproductive Center team, Ivy Fertility now includes 75 physicians across 18 practices and 35 locations in 12 states.

To learn more about Sage Reproductive Center and Ivy Fertility, visit www.SageReproductive.com and www.IvyFertility.com.

About Sage Reproductive Center

Sage Reproductive Center is the premier Midwestern destination for comprehensive familyâbuilding services include diagnostic testing, egg freezing, IVF and Ivy's proprietary Gentle IVF, male infertility treatment, LGBTQ+ and third-party reproduction options, and support for recurrent pregnancy loss. The organization includes six clinics across the Midwestern U.S., including St. Louis, Milwaukee and Chicago. Sage Reproductive Center is part of Ivy Fertility; a leading national fertility company focused on compassionate and comprehensive familyâbuilding care.

About Ivy Fertility

Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in-vitro fertilization, third-party reproduction, andrology, and fertility research. Ivy is the originator of Gentle IVF, a patient-centered approach to treatment that reduces the physical and emotional burden of care without compromising outcomes. Ivy Fertility includes Celenova Fertility, Dallas IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, Idaho Fertility Center, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Northern California Fertility Medical Center, NOVA IVF, Pacific Northwest Fertility, Reproductive Partners Medical Group, Sage Reproductive Center, San Diego Fertility Center, Santa Barbara Fertility Center, Utah Fertility Center, and Virginia Fertility & IVF. By developing new procedures such as Gentle IVF, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to exceptional outcomes and continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents.

SOURCE Ivy Fertility

Share this article

U.S.-designed and manufactured AEON⢠surgical stapling systems to support minimally invasive care for veterans, service members and their families

ALEXANDRIA, Va., Nov. 2, 2026 /PRNewswire/ -- MellingMedical today announced a strategic relationship with Lexington Medical, a U.S. medical device manufacturer focused exclusively on surgical stapling technology. Through the collaboration, MellingMedical will leverage its federal healthcare contracting expertise and status as an SBA-verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to expand access to Lexington Medical's AEON⢠surgical stapling systems for providers caring for veterans, active-duty service members and their families.

"Lexington Medical brings a rare combination of focused engineering, clinical innovation and American manufacturing to surgical stapling," said Chris Melling, founder and CEO of MellingMedical. "Its AEON platform gives surgeons versatile options for tissue management in minimally invasive procedures. We look forward to helping federal healthcare providers evaluate and access this technology."

EXPANDING FEDERAL ACCESS

The collaboration is intended to streamline federal customers' access to Lexington Medical's surgical stapling portfolio through MellingMedical's established contracting channels. Designed and manufactured in Bedford, Massachusetts, Lexington Medical's products pair domestic manufacturing with a specialized approach to surgical instrument development.

PURPOSE-BUILT SURGICAL STAPLING TECHNOLOGY

Lexington Medical's AEON platform includes the AEON+⢠manual stapler and AEON⢠Powered Stapling System, both supported by a broad range of specialized reload configurations. The reload portfolio includes proprietary Short Tip options designed for access in confined anatomy, along with choices suited to different tissue types and surgical applications. AEON Powered incorporates intelligent firing technology that adjusts firing speed in response to tissue feedback, while AEON+ offers smooth firing and articulation. The systems are designed to support superior staple formation in thoracic, bariatric, colorectal, hepatopancreatobiliary and general surgical procedures. With millions of units shipped globally and backed by superior head-to-head clinical data, the singular focus on stapling and continuous innovation offers a superior surgical stapling option.

"Our mission is to advance surgical stapling through focused engineering and continuous innovation informed by surgeons," said Leon Amariglio, founder and CEO of Lexington Medical. "We design and manufacture AEON in the United States, with both powered and manual options and a specialized reload portfolio built for the demands of minimally invasive surgery. Working with MellingMedical creates an important pathway to bring these capabilities to surgeons serving veterans and military families."

UNDERSTANDING THE MARKETPLACE

The federal healthcare system represents a significant opportunity to broaden access to innovative medical technologies. As procurement processes and care delivery needs evolve, MellingMedical's federal contracting infrastructure and experience can help Lexington Medical navigate purchasing pathways and engage providers across the Veterans Health Administration, Department of Defense and other federal healthcare settings.

A COMMITMENT TO SERVICE

In conclusion, Chris Melling said, "As federal healthcare systems modernize and cut the red tape that has often slowed down procurement, we have an unprecedented opportunity to elevate the standard of care. By aligning with forward-thinking innovators like Lexington Medical, we are leaning into this new momentum to ensure that state-of-the-art surgical tools reach our clinicians fasterâultimately delivering the exceptional, high-value outcomes our veterans have earned." 

About MellingMedical

MellingMedical, an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), holds a Medical Equipment and Surgical Federal Supply Schedule (Med/Surg), as well as a Pharmaceutical Schedule and ECAT capabilities, providing innovative and cost-effective healthcare solutions to all 172 VA Medical Centers and 1,138 VA Outpatient Clinics, all seven (7) VA CMOPs, 95 DoD Medical Facilities and Health and Human Services (HHS), including Indian Health Services (IHS) and the Center for Disease Control (CDC). To learn more, visit MellingMedical.com.

About Lexington Medical

Founded in 2013 and headquartered in Bedford, Massachusetts, Lexington Medical, Inc is a U.S. medical device company dedicated exclusively to surgical stapling. Its AEON⢠platform includes manual and powered endoscopic staplers and a broad portfolio of specialized reloads designed to support precision, access and consistent staple formation across a range of minimally invasive procedures. Lexington Medical combines product development, manufacturing and quality control in a vertically integrated U.S. operation, enabling rapid innovation informed by surgeon feedback. AEON staplers have been used in more than 100,000 procedures globally. To learn more, visit lexington-med.com.

SOURCE MellingMedical

Share this article

Eight service lines reflect the firm's investment in a comprehensive suite of advisory capabilities to better serve clients

ST. LOUIS, Nov. 2, 2026 /PRNewswire/ -- Anders announced a formal structure for its advisory practice, with eight service lines organized into two groups: Integrated Operations and Strategy & Transformation. Anders' advisory practice operates alongside the firm's tax and audit practices.

The new structure follows several years of investment in Anders' advisory capabilities through strategic acquisitions, experienced hires and the introduction of new services. Since the firm's 2022 merger with Summit CPA Group, its Virtual CFO practice has nearly doubled. More recently, Anders added Human Capital, Operations Transformation and Transaction Advisory, further broadening the services available to clients.

The structure reflects the breadth of Anders' advisory capabilities, with services spanning ongoing operational support and specialized expertise to address business challenges.

Integrated Operations: Ongoing operational services anchored in finance and technology.

- Technology Managed Services: Outsourced and co-managed IT services that combine day-to-day technology management, cybersecurity, and strategic guidance to help businesses operate efficiently, reduce risk, and maximize their technology investments.

- Virtual CFO: Flexible, subscription-based financial leadership for growing businesses that need CFO-level expertise without hiring a full-time CFO, helping them improve financial visibility, make informed decisions, and plan for growth.

Strategy & Transformation: Deep expertise in finance, people, technology and operations.

- AI & Technology: AI strategy and adoption, technology implementation, process automation, and workflow optimization to reduce manual work, improve productivity, and unlock greater value from technology investments.

- Finance Transformation: Improving financial processes, technology, reporting, and organizational structures to create more effective, scalable finance functions that deliver timely insights and stronger financial controls.

- Human Capital: End-to-end HR strategy and expertise spanning HR operations, talent acquisition and management, employee experience, and workforce strategies aligned with business goals.

- Operations Transformation: Identifying and addressing the root causes of operational challenges through practical improvements that increase efficiency, profitability, and overall business performance.

- Strategic Planning: Strategic assessment, planning, and leadership alignment, supported by actionable roadmaps and accountability frameworks that turn organizational priorities into measurable results.

- Transaction Advisory: Guidance throughout the transaction lifecycle, including financial due diligence, deal structuring, negotiations, and post-close integration planning to manage risk and maximize transaction value.

"We've been intentional about growing our advisory practice because we want to help clients beyond their tax and accounting needs," said Robert Minkler Jr., Anders CEO. "Our clients come to us with questions about all aspects of their businesses. We've invested in the people and capabilities to help them find answers and make better decisions."

"We've spent the past several years expanding our advisory capabilities to build on the tax and audit expertise that has long been a foundation of Anders," said David Hartley, partner-in-charge of advisory at Anders. "When a client comes to us with a challenge involving their finances, technology, people or operations, we can bring together specialists from across the firm to understand the bigger picture and help them move forward."

About Anders

For more than 60 years, Anders has delivered full-service accounting, tax, audit and advisory services to growth-oriented companies, organizations and individuals. Ranked #76 on Accounting Today's List of Top Accounting Firms and a top-four firm headquartered in the Midwest, Anders is a member firm of LEA Global (LEA), one of the largest international associations of independent accounting firms. For more information on Anders, visit anderscpa.com.

Media Contact

Krista Westfall, Brand Marketing Senior Manager | [email protected]

SOURCE Anders

Share this article

- Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes

- ATNM-400 is a first-in-class targeted alpha therapy directed against HER3, a driver of tumor biology and treatment resistance in multiple solid tumors

- Breast cancer findings reinforce ATNM-400's pan-tumor potential, building on previously reported preclinical results in non-small cell lung, colorectal and ovarian cancers

NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that an abstract highlighting preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes has been accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8â11, 2026, in San Antonio, Texas.

The presentation will feature ATNM-400, the Company's investigational, first-in-class Actinium-225 (²²âµAc) antibody radioconjugate targeting HER3, an antigen implicated in tumor survival and treatment resistance. ATNM-400 combines the targeting specificity of a monoclonal antibody with potent alpha-particle radiation to deliver a tumor-directed cytotoxic payload.

The breast cancer findings build on previously reported preclinical results demonstrating antitumor activity in non-small cell lung cancer (NSCLC) models across EGFR, KRAS and ALK alterations, enhanced responses with standard-of-care therapies in colorectal cancer (CRC) models, and durable activity in ovarian cancer models, including treatment-resistant disease. Together, these findings reinforce ATNM-400's pan-tumor potential and support further evaluation as a standalone therapy and in combination with established treatments across multiple solid tumor indications, complementing its ongoing clinical development in prostate cancer.

"We are excited to showcase ATNM-400's activity in therapy-resistant breast cancer models at SABCS," said Sandesh Seth, Actinium's Chairman and CEO. "Building on our previously reported NSCLC, colorectal and ovarian cancer results, these findings strengthen our vision for developing ATNM-400 as a pan-cancer radiotherapy. HER3 is implicated in resistance to standard-of-care therapies across several solid tumors and treatment settings, which implies  ATNM-400's potential extends well beyond a single oncology setting. Together with our ongoing first-in-human prostate cancer program, this growing body of evidence supports our strategy to pursue ATNM-400's broad potential and address treatment-resistant disease across large patient populations." 

ATNM-400 SABCS 2026 Presentation Details

Abstract Title: ATNM-400 a first-in-class targeted alpha therapy targeting a driver of tumor biology and treatment resistance demonstrates efficacy across therapy-resistant breast cancer subtypes

Abstract Number: 1626

Presentation Number: P2-12-17

Presentation Type: Poster presentation

Presentation Date & Time: Wednesday, December 9, 2026, 5:00â6:30 p.m. CST

Location: Exhibit Hall

About ATNM-400 and HER3

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the â¸â¹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²âµAc. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591-Tx, Clarity Pharmaceuticals' â¶â·Cu-SAR-bisPSMA, Convergent Therapeutics' CONV01-α, AstraZeneca's AZD2265 (formerly FPI-2265), Curium's lutetium-177 zadavotide guraxetan (¹â·â·Lu-PSMA-I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

HER3, also known as ERBB3, is a member of the epidermal growth factor receptor family involved in signaling pathways that support tumor growth, survival and resistance to treatment. HER3-directed antibody-drug conjugates in clinical development include BioNTech and MediLink's BNT326/YL202, Bristol Myers Squibb and SystImmune's EGFR Ã HER3 bispecific ADC izalontamab brengitecan (iza-bren), and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd). These programs underscore the clinical development interest in HER3 as an oncology target. ATNM-400 applies a distinct payload strategy, using alpha radiation in place of a conventional cytotoxic drug. Its preclinical activity in prostate, non-small cell lung and breast cancer models supports investigation as a potential pan-cancer radiotherapy, as a monotherapy and in rational combinations.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets HER3, an antigen distinct from PSMA, and is in a first-in-human Phase 1 study in metastatic castration-resistant prostate cancer (mCRPC), with preclinical activity across mCRPC, NSCLC, breast, colorectal and ovarian cancers. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investor Contact

Peter (PJ) Kelleher

LifeSci Advisors

[email protected]

(617) 430-7579

SOURCE Actinium Pharmaceuticals, Inc.

Share this article